TotalMarketCap

Adaptive Biotechnologies

ADPTNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$4.346 B

$26.85 +0.51%

Close of 6 Nov 2026

As of 6 Nov 2026, Adaptive Biotechnologies (ADPT) has a market capitalization of $4.35B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$277.0M

#2150 by revenue

Earnings

-$59.5M

Loss-making

Shares outstanding

161,876,694

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #22Scholar RockSRRK$5.56B
  2. #23CRISPR TherapeuticsCRSP$4.71B
  3. #24Adaptive BiotechnologiesADPT$4.35B
  4. #25Relay TherapeuticsRLAY$3.76B
  5. #26Iovance BiotherapeuticsIOVA$3.49B

What if Adaptive Biotechnologies were worth as much as…

Open the what-if tool →

Gold $28.2T

$174,434.46

Per share 6,498× higher

Bitcoin $1.53T

$9,438.34

Per share 352× higher

Apple $5.02T

$30,985.21

Per share 1,154× higher

Or at a round number

$10.0B$20.0B$50.0B$100.0B

Where these numbers come from

Share counts and financials for Adaptive Biotechnologies are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.